Developing an Effective Peptide-Based Vaccine for COVID-19: Preliminary Studies in Mice Models

Simple item page
dc.citation.articleNumber449
dc.citation.issueNumber3
dc.citation.journalTitleViruses
dc.citation.volumeNumber14
dc.contributor.authorYang, Haiqiang
dc.contributor.authorCao, Jessica
dc.contributor.authorLin, Xiaoyang
dc.contributor.authorYue, Jingwen
dc.contributor.authorZieneldien, Tarek
dc.contributor.authorKim, Janice
dc.contributor.authorWang, Lianchun
dc.contributor.authorFang, Jianmin
dc.contributor.authorHuang, Ruo-Pan
dc.contributor.authorBai, Yun
dc.contributor.authorSneed, Kevin
dc.contributor.authorCao, Chuanhai
dc.date.accessioned2022-03-17T15:47:55Z
dc.date.available2022-03-17T15:47:55Z
dc.date.issued2022
dc.description.abstractCoronavirus disease 2019 (COVID-19) has caused massive health and economic disasters worldwide. Although several vaccines have effectively slowed the spread of the virus, their long-term protection and effectiveness against viral variants are still uncertain. To address these potential shortcomings, this study proposes a peptide-based vaccine to prevent COVID-19. A total of 15 B cell epitopes of the wild-type severe acute respiratory coronavirus 2 (SARS-CoV-2) spike (S) protein were selected, and their HLA affinities predicted in silico. Peptides were divided into two groups and tested in C57BL/6 mice with either QS21 or Al(OH)3 as the adjuvant. Our results demonstrated that the peptide-based vaccine stimulated high and durable antibody responses in mice, with the T and B cell responses differing based on the type of adjuvant employed. Using epitope mapping, we showed that our peptide-based vaccine produced antibody patterns similar to those in COVID-19 convalescent individuals. Moreover, plasma from vaccinated mice and recovered COVID-19 humans had the same neutralizing activity when tested with a pseudo particle assay. Our data indicate that this adjuvant peptide-based vaccine can generate sustainable and effective B and T cell responses. Thus, we believe that our peptide-based vaccine can be a safe and effective vaccine against COVID-19, particularly because of the flexibility of including new peptides to prevent emerging SARS-CoV-2 variants and avoiding unwanted autoimmune responses.
dc.identifier.citationYang, Haiqiang, Cao, Jessica, Lin, Xiaoyang, et al.. "Developing an Effective Peptide-Based Vaccine for COVID-19: Preliminary Studies in Mice Models." <i>Viruses,</i> 14, no. 3 (2022) MDPI: https://doi.org/10.3390/v14030449.
dc.identifier.doihttps://doi.org/10.3390/v14030449
dc.identifier.urihttps://hdl.handle.net/1911/112023
dc.publisherMDPI
dc.rightsThis is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/
dc.titleDeveloping an Effective Peptide-Based Vaccine for COVID-19: Preliminary Studies in Mice Models
dc.typeJournal article
dc.type.dcmiText
dc.type.publicationpublisher version
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
viruses-14-00449-v2.pdf
Size:
2.42 MB
Format:
Adobe Portable Document Format
Description:
Download
Collections
Rice Coronavirus Research